Overactive bladder (OAB) is a chronic and disabling condition that affects millions of people worldwide, significantly impacting physical, psychological, and social well-being. An estimated 183 million people worldwide suffer from overactive bladder, highlighting its global prevalence.1 While OAB is more common in older adults, it can also affect younger individuals. The condition’s hallmark symptoms—frequent urination, urgency, and incontinence—can disrupt daily activities, contribute to sleep disturbances, anxiety, and depression, reducing a person’s overall quality of life.
To manage these symptoms, patients typically rely on anticholinergic medications, which work by relaxing the detrusor muscle in the bladder. While effective, these drugs target muscarinic receptors found throughout the body, leading to side effects such as dry mouth, constipation, heart palpitations, and cognitive impairment. Growing evidence has linked these medications—including oxybutynin, solifenacin, and tolterodine—to an increased risk of dementia, with a BMJ Medicine study reporting an 18% higher risk in those using anticholinergics for overactive bladder. Additionally, animal studies and EEG analyses suggest that oxybutynin can impair learning, memory, and neuronal activity. In response, regulatory agencies like the FDA now advise close monitoring of cognitive side effects in patients taking oxybutynin-containing drugs.2 3
As concerns over cognitive health grow, safer alternatives and personalized treatment strategies are gaining attention. Newer β3-adrenergic agonists, such as mirabegron, offer a promising alternative by treating OAB without targeting muscarinic receptors. Additionally, human tissue-based research and personalized medicine approaches—factoring in genetic markers, biomarkers, and individual drug responses—may help develop more effective, tailored treatments with fewer side effects. As research progresses, a shift toward precision medicine and targeted therapies could transform OAB treatment and improve long-term patient outcomes.
The Link Between Overactive Bladder and Cognitive Decline
Growing evidence suggests a strong correlation between overactive bladder and cognitive decline, with recent research highlighting depression as a key factor in this relationship. A study using NHANES data found that cognitive scores were significantly lower in individuals with OAB compared to those without, with a mean cognitive decline of 0.17 standard deviations. Additionally, 15% of OAB patients in the study had depression, more than double the rate in the non-OAB group (6.05%). Data shows that depression mediates 34.56% of the association between OAB and cognitive health, suggesting that mental health symptoms may exacerbate cognitive impairment in those with bladder dysfunction.4 The interplay between OAB and wider neurological symptoms is becoming apparent. Growing evidence suggests a strong correlation between overactive bladder and cognitive decline, with recent research highlighting depression as a key factor in this relationship.
A study led by Ling Liu in Beijing, China, confirmed that cognitive scores were consistently lower in individuals with OAB across all tests supporting claims of depression as a mediator in OAB-related cognitive decline. These findings highlight the complex relationship between urinary health, mental health, and cognitive function, emphasizing the need for early detection and intervention. Psychiatrists and healthcare professionals should consider urinary symptoms when assessing older adults for cognitive decline, as addressing overactive bladder may play a crucial role in preserving cognitive health.5
As research continues to explore the bladder-brain axis, it is becoming clear that cognitive health must be a key consideration in bladder drug discovery. The neural network connecting the bladder and brain, including the sympathetic and parasympathetic nervous systems, plays a fundamental role in bladder control. Any drug targeting bladder function has the potential to impact these neural pathways, leading to unintended cognitive side effects. Given the increased dementia risk associated with anticholinergic OAB treatments, ensuring that new therapies are both effective and cognitively safe is essential for protecting vulnerable patient populations.
Anticholinergic Overactive Bladder Treatments and Dementia Risk
Anticholinergic medications are prescribed for overactive bladder to reduce involuntary bladder contractions. The most frequently used include oxybutynin, solifenacin, fesoterodine, darifenacin, tolterodine, and trospium. While these drugs can be effective in managing symptoms, emerging research has raised concerns about their long-term impact on cognitive health.5
A recent BMJ Medicine study found a significant association between certain anticholinergic OAB drugs and an increased risk of dementia. Specifically, oxybutynin hydrochloride, solifenacin succinate, and tolterodine tartrate are linked to a higher likelihood of developing dementia, while other drugs like darifenacin, fesoterodine, and trospium did not show the same risk. The study reported an adjusted odds ratio of 1.18, suggesting that any anticholinergic OAB drug may modestly increase the likelihood of dementia, with stronger associations observed in men and individuals under 80 years old at the time of diagnosis. Notably, oxybutynin has substantial evidence linking it to cognitive impairment, as confirmed by sleep studies and quantitative EEG analyses. These findings indicate that early exposure to these medications could have lasting neurological consequences, emphasizing the need for careful patient monitoring and alternative treatment options. 6
Recognizing these risks, the FDA has added a warning to oxybutynin-containing products under the "Central Nervous System Effects" label, advising that patients are monitored for signs of cognitive decline, particularly in the first few months of treatment or after a dosage increase. Research has also found a dose-dependent relationship between long-term anticholinergic use and dementia risk, with cumulative exposure over 10 years significantly increasing the likelihood of developing both dementia and Alzheimer’s disease. These findings underscore the importance of raising awareness among healthcare providers and older adults about the cognitive risks of prolonged anticholinergic use. Moving forward, reducing reliance on high-risk anticholinergics and exploring safer alternatives will be crucial in balancing effective OAB management with long-term brain health.7, 8
Rethinking Bladder Drug Discovery
Given the cognitive risks associated with certain anticholinergic drugs, healthcare providers and patients should consider safer alternatives. Mirabegron, a β3-adrenoceptor agonist, has higher variability but maintains a lower dementia risk profile, making it a preferable option when compared to potential alternatives. Additionally, non-pharmacological interventions such as pelvic floor therapy, bladder training, dietary adjustments, and lifestyle modifications can be effective in managing OAB symptoms. For patients requiring medication, alternative anticholinergic drugs with a lower dementia risk—such as darifenacin, fesoterodine fumarate, and trospium chloride—offer potentially safer choices. 10
Beyond existing treatments, investigating new drug targets and pathways is crucial for advancing bladder health. One promising approach is Botulinum toxin type A (BoNT/A) injections, which can reduce urinary urgency and incontinence episodes by blocking neuromuscular transmission and temporarily relaxing the bladder muscle. Several randomized controlled trials (RCTs) have demonstrated that BoNT/A significantly reduces incontinence episodes, with effects lasting six to nine months. Additionally, researchers are exploring liposome-based BoNT/A delivery systems as a potential alternative method for treating OAB. While no RCTs have directly investigated probiotics for OAB treatment, studies suggest differences in the urinary microbiota of individuals with and without urinary incontinence, highlighting an area for future research.11
A key factor in developing safer, more effective OAB drugs is the use of human tissue-based research. Many drug candidates fail in clinical trials due to toxicity or lack of efficacy, often because animal models do not fully replicate human biology. By utilizing fresh human tissue from ethically sourced donors, researchers can study disease pathology and drug responses in real-time, leading to earlier identification of safety concerns and a higher likelihood of clinical success. 12 As the field of bladder drug discovery evolves, human tissue models will play an essential role in ensuring that new therapies are both effective and safe—without exacerbating cognitive decline in at-risk populations.
Future Directions in Overactive Bladder Research and Treatment
The future of overactive bladder treatment lies in personalized medicine, shifting away from a one-size-fits-all approach to tailored therapies that optimize efficacy while minimizing risks. Research shows that factors such as age, sex, hormonal balance, neurological health, and inflammation levels influence both disease progression and drug response. Biomarker research—analyzing markers in urine, blood, or bladder tissue—could help identify the root causes of bladder dysfunction, distinguishing neurologically driven OAB from muscular issues.13
Genetic testing and neurogenic biomarkers could further refine treatment strategies, enabling earlier interventions for high-risk individuals. Human bladder tissue models offer another promising approach, allowing researchers to evaluate drug responses in diseased tissue before conducting clinical trials. This ex vivo screening could help determine which therapies—such as newer β3-adrenergic agonists like mirabegron—are best suited for patients at risk of cognitive decline from anticholinergics. As research advances, precision medicine will be key in developing safer, more effective overactive bladder treatments, improving patient outcomes while reducing adverse effects. 14, 15
Conclusion
The evolving landscape of overactive bladder treatment underscores the necessity for therapies that are both effective and cognizant of cognitive health. Traditional anticholinergic medications, while beneficial for symptom management, have been linked to increased dementia risk, particularly in older adults. This association emphasizes the importance of exploring alternative treatments that mitigate such risks.
Emerging therapies, such as β3-adrenergic agonists like mirabegron and vibegron, offer promising alternatives by targeting bladder function without the cognitive side effects associated with anticholinergics. Additionally, potassium channel activators are garnering attention for their role in modulating detrusor smooth muscle activity. By enhancing potassium efflux, these agents help stabilize the bladder muscle's resting membrane potential, thereby reducing involuntary contractions and improving bladder storage capacity.
The integration of human tissue-based research is pivotal in this context. Utilizing fresh human bladder tissue allows for a more accurate assessment of drug efficacy and safety, bridging the gap between preclinical studies and clinical outcomes. This approach not only facilitates the identification of potential adverse effects early in the drug development process but also supports the advancement of personalized medicine strategies tailored to individual patient profiles.
In summary, the future of OAB management lies in a multifaceted approach that combines innovative pharmacological developments, such as β3-adrenergic agonists and potassium channel activators, with cutting-edge research methodologies. Emphasizing patient-specific factors and leveraging human tissue assays will be instrumental in developing therapies that are both safe and effective, ultimately enhancing the quality of life for those affected by OAB.16, 17
References
1. St Pete Urology. “How Common Is Overactive Bladder? Prevalence, Risk Factors, and Statistics.” St Pete Urology, 6 Sept. 2023, https://stpeteurology.com/how-common-is-overactive-bladder-prevalence-risk-factors-and
2. Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment Chancellor, Michael B. et al. Urology, Volume 186, 123 - 129.
3. Katz, I.R., Sands, L.P., Bilker, W., DiFilippo, S., Boyce, A. and D'Angelo, K. (1998), Identification of Medications That Cause Cognitive Impairment in Older People: The Case of Oxybutynin Chloride. Journal of the American Geriatrics Society, 46: 8-13. https://doi.org/10.1111/j.1532-5415.1998.tb01006.x
4, 5. Liu, L. Exploring the Association Between Overactive Bladder (OAB) and Cognitive decline: mediation by depression in elderly adults, a NHANES weighted analysis. Sci Rep 15, 3669 (2025). https://doi.org/10.1038/s41598-025-86267-6
6. “Anticholinergics for Overactive Bladder: Medication List and More.” Medical News Today, MediLexicon International, www.medicalnewstoday.com/articles/anticholinergic-for-overactive-bladder#side-effects. Accessed 24 Apr. 2025.
7. Barbara Iyen, Carol Coupland, Brian Gregory Bell, Darren M Ashcroft, Martin William Orrell, Delia Bishara, Tom Dening, Anthony J Avery - Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study: BMJ Medicine 2024;3:e000799.
8. Kay, G. G., & Ebinger, U. (2008). Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. International journal of clinical practice, 62(11), 1792–1800. https://doi.org/10.1111/j.1742-1241.2008.01849.
9. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study. JAMA Intern Med. 2015;175(3):401–407. doi:10.1001/jamainternmed.2014.7663
10, 11. Randa Zoqlam, Sandra Lazauskaite, Scott Glickman, Lyubov Zaitseva, Petre-Cristian Ilie, Sheng Qi, Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases, European Journal of Pharmaceutical Sciences, Volume 173, 2022, 106167, ISSN 0928-0987, https://doi.org/10.1016/j.ejps.2022.106167.
12. Advisors, Boston Biotech. “Understanding Drug Development Failures: Why 90% of Candidates Fail.” Boston Biotech Advis, Boston Biotech Advis, 24 Sept. 2024, www.bostonbiotechadvisors.com/post/understanding-drug-development-failures-why-90-of-candidates-fail#:~:text=One%20of%20the%20primary%20reasons%20drug%20candidates%20fail,%28in%20animals%29%20to%20predict%20their%20effectiveness%20in%20humans.
13, 14. Lee K. S. (2015). Future directions in overactive bladder treatment: Personalized medicine can be applied?. Korean journal of urology, 56(10), 671–672. https://doi.org/10.4111/kju.2015.56.10.671
15. Rufus Cartwright, Anna C. Kirby, Kari A.O. Tikkinen, Altaf Mangera, Gans Thiagamoorthy, Prabhakar Rajan, Jori Pesonen, Chris Ambrose, Juan Gonzalez-Maffe, Phillip Bennett, Tom Palmer, Andrew Walley, Marjo-Riitta Järvelin, Chris Chapple, Vik Khullar, Systematic review and metaanalysis of genetic association studies of urinary symptoms and prolapse in women, American Journal of Obstetrics and Gynecology, Volume 212, Issue 2, 2015, Pages 199.e1-199.e24, ISSN 0002-9378, https://doi.org/10.1016/j.ajog.2014.08.005.
16. Aizawa, N., Wakamatsu, D., Kida, J., Otsuki, T., Saito, Y., Matsuya, H., Homma, Y. and Igawa, Y. (2017), Inhibitory effects of retigabine, a Kv7 channel activator, on mechanosensitive primary bladder afferent activities and nociceptive behaviors in rats. Neurourol. Urodynam. , 36: 280-285. https://doi.org/10.1002/nau.22920
17. Malysz, J., & Petkov, G. V. (2020). Detrusor Smooth Muscle KV7 Channels: Emerging New Regulators of Urinary Bladder Function. Frontiers in physiology, 11, 1004. https://doi.org/10.3389/fphys.2020.01004
